Advertisement

Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications

Published:September 05, 2015DOI:https://doi.org/10.1016/j.trsl.2015.08.008
      Vaccines hold promise both for the prevention of infections and as potential immunologic therapy for patients with autoimmune disease (AD). These patients are at high risk for both common and opportunistic infections, but this risk can be significantly reduced and even obviated with the use of recommended available vaccines. Unfortunately, patients with ADs are not routinely offered or provided indicated vaccinations and have higher rates of complications from vaccine-preventable illnesses than patients without ADs. In addition, vaccine therapy is currently under study for the treatment of autoimmune disorders, with early studies demonstrating immunomodulatory effects that may counter undesired immune activation and alleviate disease activity.

      Abbreviations:

      IS (immunosuppressive), AD (autoimmune disease), HIV (human immunodeficiency virus), PCP (pneumocystis pneumonia), VE (vaccine efficacy), ANCA (antineutrophil cytoplasmatic antibodies), SLE (systemic lupus erythematosus), ASIA (autoimmune inflammatory syndrome induced by adjuvants), ACIP (Advisory Committee on Immunization Practices), CDC (Centers for Disease Control and Prevention), EULAR (the European League Against Rheumatism), ACR (American College of Rheumatology), MMR (mumps, measles, rubella), GBS (Guillain–Barré syndrome), CAPITA (Community Acquired Pneumonia Immunization Trial in Adults), TNF (tumor necrosis factor), HZ (herpes zoster), IBD (inflammatory bowel disease), MMRV (measles, mumps, rubella and varicella vaccine), SLEDAI (Systemic Lupus Erythematosus Disease Activity Index), HPV (human papillomavirus), RA (rheumatoid arthritis), HBV (hepatitis B virus), EAE (experimental autoimmune encephalomyelitis), IL-10 (interleukin 10), TGF (transforming growth factor), DM (diabetes mellitus), Tdap (tetanus, diphtheria and acellular pertussis vaccine), Hib (Haemophillus influenza type b vaccine), IgM (immunoglobulin M), PSV23 (pneumococcal polysaccharide vaccine against 23 types of pneumococcal bacteria), PCV13 (pneumococcal conjugate vaccine against 13 types of pneumococcal bacteria), TCV (T-cell vaccination), MS (multiple sclerosis), RNP (ribonucleoprotein), DC (dendritic cell), RNA (ribonucleic acid), PBV (peptide-based vaccination), APLs (altered peptide ligands), IgG (immunoglobulin G), MBP (myelin basic protein)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kavanaugh A.
        Infection prophylaxis in antirheumatic therapy: emphasis on vaccination.
        Curr Opin Rheumatol. 2009; 21: 419-424
        • Gluck T.
        • Muller-Ladner U.
        Vaccination in patients with chronic rheumatic or autoimmune diseases.
        Clin Infect Dis. 2008; 46: 1459-1465
        • Teng G.G.
        • Curtis J.R.
        • Saag K.G.
        Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.
        Curr Opin Rheumatol. 2008; 20: 320-326
        • Sutton A.J.
        • Sweeting M.J.
        • Buchan I.
        • Matteson E.L.
        • Montori V.
        Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
        JAMA. 2006; 295: 2275-2285
        • Fransen J.
        • Kievit W.
        • Dutmer E.A.J.
        • et al.
        Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
        Rheumatology. 2013; 52: 1052-1057
        • Fransen J.
        • Kievit W.
        • Flendrie M.
        • et al.
        Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
        Ann Rheum Dis. 2013; 72: 895-900
        • Nakajima A.
        • Inoue E.
        • Shidara K.
        • et al.
        Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab.
        Mod Rheumatol. 2012; 22: 122-127
        • Strangfeld A.
        • Kary S.
        • Rau R.
        • et al.
        Infections in patients with rheumatoid arthritis treated with biologic agents.
        Arthritis Rheum. 2005; 52: 3403-3412
        • Yu H.M.
        • Jun J.B.
        • Jeon H.-S.
        • Yoo W.-H.
        Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide.
        Mod Rheumatol. 2013; 23: 709-715
        • Kourbeti I.S.
        • Ziakas P.D.
        • Mylonakis E.
        Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis.
        Clin Infect Dis. 2014; 58: 1649-1657
        • Holland S.M.
        Antimicrobial prophylaxis for primary immunodeficiencies.
        Curr Opin Allergy Clin Immunol. 2009; 9: 525-530
        • Oka S.
        Pneumocystis jirovecii pneumonia in kidney transplantation.
        Transpl Infect Dis. 2011; 13: 551-558
        • Paul M.
        • Vidal L.
        • Leibovici L.
        Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.
        Mayo Clin Proc. 2007; 82: 1052-1059
        • Benson C.
        • Holmes K.K.
        • Brooks J.T.
        • et al.
        Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
        MMWR Recomm Rep. 2009; 58 (quiz CE1–4): 1-207
        • Meuli K.
        • Chapman P.
        • O'Donnell J.
        • Frampton C.
        • Stamp L.
        Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period.
        Intern Med J. 2007; 37: 687-692
        • Roblot F.
        Management of Pneumocystis pneumonia in patients with inflammatory disorders.
        Expert Rev Anti Infect Ther. 2005; 3: 435-444
        • Kim D.
        • Bridges C.
        • Harriman K.
        Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older—United States, 2015.
        MMWR Morb Mortal Wkly Rep. 2015; 64: 91-92
        • Mercado U.
        Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus?.
        J Rheumatol. 2006; 33: 1469-1471
        • Adeeb F.
        • Eltahir A.
        • Harney S.
        The uptake of influenza and pneumococcal vaccination among immunocompromised patients attending rheumatology outpatient clinics.
        Joint Bone Spine. 2011; 78: 374-377
        • Pradeep J.
        • Watts R.
        • Clunie G.
        Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis.
        Ann Rheum Dis. 2007; 66: 837-838
        • Mitchell W.S.
        An audit of influenza and pneumococcal vaccination in rheumatology outpatients.
        BMC Musculoskelet Disord. 2007; 8: 58
        • Desai S.P.
        • Lu B.
        • Szent-Gyorgyi L.E.
        • et al.
        Increasing pneumococcal vaccination for immunosuppressed patients: a cluster quality improvement trial.
        Arthritis Rheum. 2013; 65: 39-47
        • van Assen S.
        • Agmon-Levin N.
        • Elkayam O.
        • et al.
        EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.
        Ann Rheum Dis. 2011; 70: 414-422
      1. Center for Disease Control and Prevention. Vaccine information for adults. 2015 [updated September 18, 2014; February 17, 2015]; Available at: http://www.cdc.gov/vaccines/adults/rec-vac/index.html. Accessed February 17, 2015.

        • L'Huillier A.G.
        • Posfay-Barbe K.M.
        Live viral vaccines in immunocompromised patients.
        Future Virology. 2014; 9: 161-171
        • Son M.
        • Shapiro E.
        • LaRussa P.
        • et al.
        Effectiveness of varicella vaccine in children infected with HIV.
        J Infect Dis. 2010; 201: 1806-1810
        • Taweesith W.
        • Puthanakit T.
        • Kowitdamrong E.
        • et al.
        The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children.
        Pediatr Infect Dis J. 2011; 30: 320-324
        • Weinberg A.
        • Levin M.
        • Macgregor R.
        Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults.
        Hum Vaccin. 2010; 6: 318-321
        • Maglione M.A.
        • Das L.
        • Raaen L.
        • et al.
        Safety of vaccines used for routine immunization of U.S. children: a systematic review.
        Pediatrics. 2014; 134: 325-337
        • Destefano F.
        • Pfeifer D.
        • Nohynek H.
        Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data.
        Bull World Health Organ. 2008; 86: 373-380
        • Moro P.L.
        • Jankosky C.
        • Menschik D.
        • et al.
        Adverse events following Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990-2013.
        J Pediatr. 2015; 166: 992-997
        • Fisher M.
        Vaccine safety.
        Pediatr Infect Dis J. 2008; 27: 827-830
        • Melmed G.
        Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics.
        Inflamm Bowel Dis. 2009; 15: 1410-1416
        • Wharton M.
        Vaccine safety: current systems and recent findings.
        Curr Opin Pediatr. 2010; 22: 88-93
        • Broder K.
        Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience.
        Expert Rev Vaccines. 2008; 7: 75-82
        • Agmon-Levin N.
        • Blank M.
        • Chapman J.
        • Shoenfeld Y.
        Guillain-Barre syndrome–a classical autoimmune disease triggered by infection or vaccination.
        Clin Rev Allergy Immunol. 2012; 42: 121-130
        • Lancet TEoT
        Retraction—ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.
        Lancet. 2010; 375: 445
        • Epperson S.
        • Blanton L.
        • Kniss K.
        • et al.
        Influenza activity—United States, 2013-14 season and composition of the 2014-15 influenza vaccines.
        MMWR Morb Mortal Wkly Rep. 2014; 63: 483-490
        • Papadopoulou D.
        • Sipsas N.V.
        Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases.
        Rheumatol Int. 2014; 34: 151-163
        • deBruyn J.
        • Hilsden R.
        • Fonseca K.
        • et al.
        Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease.
        Inflamm Bowel Dis. 2012; 18: 25-33
        • Lu Y.
        • Jacobson D.
        • Ashworth L.
        • et al.
        Immune response to influenza vaccine in children with inflammatory bowel disease.
        Am J Gastroenterol. 2009; 104: 444-453
        • Mathian A.
        • Devilliers H.
        • Krivine A.
        • et al.
        Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus.
        Arthritis Rheum. 2011; 63: 3502-3511
        • Holvast A.
        • Huckriede A.
        • Wilschut J.
        • et al.
        Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.
        Ann Rheum Dis. 2006; 65: 913-918
        • Anton A.
        • Pumarola T.
        Influenza in immunocompromised patients: considerations for therapy.
        Future Virology. 2011; 6: 855-868
        • Azevedo L.S.
        • Gerhard J.
        • Miraglia J.L.
        • et al.
        Seroconversion of 2009 pandemic influenza A (H1N1) vaccination in kidney transplant patients and the influence of different risk factors.
        Transpl Infect Dis. 2013; 15: 612-618
        • Battafarano D.F.
        • Battafarano N.J.
        • Larsen L.
        • et al.
        Antigen-specific antibody responses in lupus patients following immunization.
        Arthritis Rheum. 1998; 41: 1828-1834
        • Boltin D.
        • Gingold-Belfer R.
        • Kimchi N.
        • et al.
        Utilization of influenza immunization in adults with Crohn's disease-a longitudinal, population-based study.
        Inflamm Bowel Dis. 2014; 20: 240-245
        • Crowe S.R.
        • Merrill J.T.
        • Vista E.S.
        • et al.
        Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.
        Arthritis Rheum. 2011; 63: 2396-2406
        • Cullen G.
        • Bader C.
        • Korzenik J.
        • Sands B.
        Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.
        Gut. 2012; 61: 385-391
        • Ershler W.B.
        Absent influenza vaccine response in rituximab-treated lymphoma patients.
        Infectious Disease Alert. 2012; 31: 67-68
        • Fairchok M.P.
        • Trementozzi D.P.
        • Carter P.S.
        • Regnery H.L.
        • Carter E.R.
        Effect of prednisone on response to influenza virus vaccine in asthmatic children.
        Arch Pediatr Adolesc Med. 1998; 152: 1191-1195
        • Franca I.L.A.
        • Ribeiro I.L.A.
        • Aikawa A.C.M.
        • et al.
        Influenza A H1N1/2009 vaccine in rheumatic disease patients under anti-TNF therapy: safety and response.
        Arthritis Rheum. 2011; 63: 2619
        • Holvast A.
        • Stegeman C.A.
        • Benne C.A.
        • et al.
        Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination.
        Ann Rheum Dis. 2009; 68 ([Erratum appears in Ann Rheum Dis. 2009 Sep;68(9):1516]): 873-878
        • Kim W.
        • Kim S.H.
        • Huh S.Y.
        • et al.
        Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab.
        Eur J Neurol. 2013; 20: 975-980
        • Woerner A.
        • Sauvain M.-J.
        • Aebi C.
        • Otth M.
        • Bolt I.B.
        Immune response to influenza vaccination in children treated with methotrexate or/and tumor necrosis factor-alpha inhibitors.
        Hum Vaccin. 2011; 7: 1293-1298
        • Muller R.
        • Maier R.
        • Hoschler K.
        • et al.
        Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination.
        Clin Exp Rheumatol. 2013; 31: 723-730
        • Dunning A.J.
        • Kimmel M.
        • Kirby D.
        • et al.
        Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
        N Engl J Med. 2014; 371: 635-645
        • Elkayam O.
        Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis.
        Clin Dev Immunol. 2006; 13: 349-351
        • Tomczyk S.
        • Bennett N.M.
        • Stoecker C.
        • et al.
        Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Morb Mortal Wkly Rep. 2014; 63: 822-825
        • Mirsaeidi M.
        • Ebrahimi G.
        • Allen M.
        • Aliberti S.
        Pneumococcal vaccine and patients with pulmonary diseases.
        Am J Med. 2014; 127: 886.e1-886.e8
        • Bonten M.J.M.
        • Huijts S.M.
        • Bolkenbaas M.
        • et al.
        Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
        N Engl J Med. 2015; 372: 1114-1125
        • Bingham III, C.O.
        • Looney R.J.
        • Deodhar A.
        • et al.
        Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
        Arthritis Rheum. 2010; 62: 64-74
        • Bingham 3rd, C.O.
        • Rizzo W.
        • Kivitz A.
        • et al.
        Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA).
        Ann Rheum Dis. 2015; 74: 818-822
        • Jarrett M.P.
        • Schiffman G.
        • Barland P.
        • Grayzel A.I.
        Impaired response to pneumococcal vaccine in systemic lupus erythematosus.
        Arthritis Rheum. 1980; 23: 1287-1293
        • Melmed G.Y.
        • Agarwal N.
        • Frenck R.W.
        • et al.
        Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease.
        Am J Gastroenterol. 2010; 105: 148-154
        • Musher D.M.
        How effective is vaccination in preventing pneumococcal disease?.
        Infect Dis Clin North Am. 2013; 27: 229-241
        • Flamaing J.
        • Rumke H.C.
        • Penzes J.
        • et al.
        A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >65 years.
        Vaccine. 2011; 29: 5195-5202
        • Sauerbrei A.
        • Rubtcova E.
        • Wutzler P.
        • Schmid D.S.
        • Loparev V.N.
        Genetic profile of an Oka varicella vaccine virus variant isolated from an infant with zoster.
        J Clin Microbiol. 2004; 42: 5604-5608
        • Ortega-Sanchez I.R.
        • Seward J.F.
        • Advisory Committee on Immunization Practices Centers for Disease C
        Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2008; 57 (quiz CE2–4): 1-30
        • Weinberg A.
        • Levin M.J.
        • Weinberg A.
        • Levin M.J.
        VZV T cell-mediated immunity.
        Curr Top Microbiol Immunol. 2010; 342: 341-357
        • Park H.B.
        • Kim K.C.
        • Park J.H.
        • et al.
        Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus.
        J Rheumatol. 2004; 31: 2151-2155
        • Pope J.E.
        • Krizova A.
        • Ouimet J.M.
        • et al.
        Close association of herpes zoster reactivation and systemic lupus erythematosus (SLE) diagnosis: case-control study of patients with SLE or noninflammatory musculoskeletal disorders.
        J Rheumatol. 2004; 31: 274-279
        • Angit C.
        • Daly B.M.
        Disseminated varicella zoster infection in a patient with rheumatoid arthritis treated with methotrexate.
        Clin Exp Dermatol. 2009; 34: e453-e454
        • Garcia-Doval I.
        • Perez-Zafrilla B.
        • Descalzo M.A.
        • et al.
        Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists.
        Ann Rheum Dis. 2010; 69: 1751-1755
        • Tresch S.
        • Trueb R.M.
        • Kamarachev J.
        • et al.
        Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanercept.
        Dermatology. 2009; 219: 347-349
        • Oxman M.N.
        • Levin M.J.
        • Johnson G.R.
        • et al.
        A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
        N Engl J Med. 2005; 352: 2271-2284
        • Gomes Silva B.N.
        • Torloni M.R.
        • Soares B.G.O.
        Vaccines for preventing herpes zoster in older adults.
        Cochrane Database Syst Rev. 2012; : CD008858
        • Tseng H.F.
        • Smith N.
        • Harpaz R.
        • et al.
        Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease.
        JAMA. 2011; 305: 160-166
        • Singh J.
        • Furst D.
        • Bharat A.
        • et al.
        2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
        Arthritis Care Res (Hoboken). 2012; 64: 625-639
        • Charkoudian L.D.
        • Kaiser G.M.
        • Steinmetz R.L.
        • Srivastava S.K.
        Acute retinal necrosis after herpes zoster vaccination.
        Arch Ophthalmol. 2011; 129: 1495-1497
        • Leung A.K.
        • Robson W.L.
        • Leong A.G.
        • et al.
        Herpes zoster in childhood.
        J Pediatr Health Care. 2006; 20: 300-303
        • Levy O.
        • Orange J.S.
        • Hibberd P.
        • et al.
        Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells.
        J Infect Dis. 2003; 188: 948-953
        • Lawless J.F.
        • Nolen T.M.
        • Sterling T.
        • et al.
        A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
        Clin Vaccine Immunol. 2008; 15: 314-319
        • Schmader K.
        • Levin M.J.
        • Gnann Jr., J.W.
        • et al.
        Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.
        Clin Infect Dis. 2012; 54: 922-928
        • Yeung C.Y.
        • Liang D.C.
        Varicella vaccine in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma.
        Pediatr Hematol Oncol. 1992; 9: 29-34
        • Redman R.L.
        • Nader S.
        • Zerboni L.
        • et al.
        Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine.
        J Infect Dis. 1997; 176: 578-585
        • Sauerbrei A.
        • Prager J.
        • Hengst U.
        • Zintl F.
        • Wutzler P.
        Varicella vaccination in children after bone marrow transplantation.
        Bone Marrow Transplant. 1997; 20: 381-383
        • Pileggi G.S.
        • de Souza C.B.S.
        • Ferriani V.P.L.
        Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.
        Arthritis Care Res (Hoboken). 2010; 62: 1034-1039
        • Akinsanya-Beysolow I.
        • Advisory Committee on Immunization P
        • Group ACAIW
        • Centers for Disease C, Prevention
        Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years—United States, 2014.
        MMWR Morb Mortal Wkly Rep. 2014; 63: 108-109
        • Scheinberg M.
        • Guedes-Barbosa L.S.
        • Mangueira C.
        • et al.
        Yellow fever revaccination during infliximab therapy.
        Arthritis Care Res (Hoboken). 2010; 62: 896-898
        • Fiebelkorn A.P.
        • Temte J.L.
        • Wallace G.S.
        • Centers for Disease C, Prevention
        Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2013; 62: 1-34
        • Herron A.
        • Dettleff G.
        • Hixon B.
        • et al.
        Influenza vaccination in patients with rheumatic diseases. Safety and efficacy.
        JAMA. 1979; 242: 53-56
        • Klippel J.H.
        • Karsh J.
        • Stahl N.I.
        • et al.
        A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus.
        Arthritis Rheum. 1979; 22: 1321-1325
        • Elkayam O.
        • Paran D.
        • Caspi D.
        • et al.
        Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus.
        Clin Infect Dis. 2002; 34: 147-153
        • Abu-Shakra M.
        • Zalmanson S.
        • Neumann L.
        • et al.
        Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity.
        J Rheumatol. 2000; 27: 1681-1685
        • Elkayam O.
        • Paran D.
        • Burke M.
        • et al.
        Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies.
        Autoimmunity. 2005; 38: 493-496
        • Del Porto F.
        • Lagana B.
        • Biselli R.
        • et al.
        Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity.
        Vaccine. 2006; 24: 3217-3223
        • Hull T.
        • Bates J.H.
        Optic neuritis after influenza vaccination.
        Am J Ophthalmol. 1997; 124: 703-704
        • Maillefert J.
        • Sibilia J.
        • Toussirot E.
        • et al.
        Rheumatic disorders developed after hepatitis B vaccination.
        Rheumatology. 1999; 38: 978-983
        • Older S.
        • Battafarano D.F.
        • Enzenauer R.J.
        • Krieg A.M.
        Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature.
        Semin Arthritis Rheum. 1999; 29: 131-139
        • Birck R.
        • Kaelsch I.
        • Schnuelle P.
        • Flores-Suarez L.F.
        • Nowack R.
        ANCA-associated vasculitis following influenza vaccination: causal association or mere coincidence?.
        J Clin Rheumatol. 2009; 15: 289-291
        • Lorenzoni P.J.
        • Scola R.H.
        • Kay C.S.K.
        • et al.
        Vasculitic neuropathy following influenza seasonal vaccination.
        Arq Neuropsiquiatr. 2012; 70: 154-155
        • Iyngkaran P.
        • Limaye V.
        • Hill C.
        • et al.
        Rheumatoid vasculitis following influenza vaccination.
        Rheumatology. 2003; 42: 907-909
        • Stassen P.
        • Sanders J.-S.F.
        • Kallenberg C.G.M.
        • Stegeman C.A.
        Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis.
        Nephrol Dial Transplant. 2008; 23: 654-658
        • Chen R.
        • Pless R.
        • Destefano F.
        Epidemiology of autoimmune reactions induced by vaccination.
        J Autoimmun. 2001; 16: 309-318
        • Rahier J.-F.
        • Moutschen M.
        • Van Gompel A.
        • et al.
        Vaccinations in patients with immune-mediated inflammatory diseases.
        Rheumatology. 2010; 49: 1815-1827
        • Croft S.M.
        • Schiffman G.
        • Snyder E.
        • et al.
        Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosus.
        J Rheumatol. 1984; 11: 141-146
        • Holvast B.
        • Huckriede A.
        • Kallenberg C.G.M.
        • Bijl M.
        Influenza vaccination in systemic lupus erythematosus: safe and protective?.
        Autoimmun Rev. 2007; 6: 300-305
        • Abu-Shakra M.
        Safety of vaccination of patients with systemic lupus erythematosus.
        Lupus. 2009; 18: 1205-1208
        • Wraith D.C.
        • Goldman M.
        • Lambert P.-H.
        Vaccination and autoimmune disease: what is the evidence?.
        Lancet. 2003; 362: 1659-1666
        • Grimaldi-Bensouda L.
        • Le Guern V.
        • Kone-Paut I.
        • et al.
        The risk of systemic lupus erythematosus associated with vaccines: an international case-control study.
        Arthritis Rheum. 2014; 66: 1559-1567
        • Grimaldi-Bensouda L.
        • Guillemot D.
        • Godeau B.
        • et al.
        Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
        J Intern Med. 2014; 275: 398-408
        • Murdaca G.
        • Orsi A.
        • Spano F.
        • et al.
        Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity.
        Autoimmun Rev. 2014; 13: 75-84
        • Perry L.
        • Winthrop K.
        • Curtis J.
        Vaccinations for rheumatoid arthritis.
        Curr Rheumatol Rep. 2014; 16: 431
        • Looney R.J.
        • Srinivasan R.
        • Calabrese L.H.
        The effects of rituximab on immunocompetency in patients with autoimmune disease.
        Arthritis Rheum. 2008; 58: 5-14
        • van Assen S.
        • Holvast A.
        • Benne C.A.
        • et al.
        Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
        Arthritis Rheum. 2010; 62: 75-81
        • Ferreira I.
        • Isenberg D.
        Vaccines and biologics.
        Ann Rheum Dis. 2014; 73: 1446-1454
        • Hua C.
        • Barnetche T.
        • Combe B.
        • Morel J.
        Effect of methotrexate, anti–tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis.
        Arthritis Care Res (Hoboken). 2014; 66: 1016-1026
        • McDonald E.
        • Jarrett M.P.
        • Schiffman G.
        • Grayzel A.I.
        Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus.
        J Rheumatol. 1984; 11: 306-308
        • Abu-Shakra M.
        • Press J.
        • Varsano N.
        • et al.
        Specific antibody response after influenza immunization in systemic lupus erythematosus.
        J Rheumatol. 2002; 29: 2555-2557
        • Aytac M.
        • Kasapcopur O.
        • Aslan M.
        • et al.
        Hepatitis B vaccination in juvenile systemic lupus erythematosus.
        Clin Exp Rheumatol. 2011; 29: 882-886
        • Ogimi C.
        • Tanaka R.
        • Saitoh A.
        • Oh-Ishi T.
        Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents.
        Pediatr Infect Dis J. 2011; 30: 208-211
        • O'Neill S.
        • Isenberg D.A.
        Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety.
        Lupus. 2006; 15: 778-783
        • Terreri M.T.R.A.
        • Rosario P.O.
        • de Moraes-Pinto M.I.
        • Silva C.A.A.
        • Hilario M.O.E.
        Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus.
        Clin Exp Rheumatol. 2012; 30: 791-798
        • Guillevin L.
        Infections in vasculitis.
        Baillieres Best Pract Res Clin Rheumatol. 2013; 27: 19-31
        • Rachael L.
        • Ying L.
        • Jeanne T.
        P-074 survey of immunization practices in inflammatory bowel disease patients amongst pediatric gastroenterologists.
        Inflamm Bowel Dis. 2014; 20: S56-S57
        • Case D.J.
        • Copeland L.A.
        • Stock E.M.
        • Herrera H.R.
        • Pfanner T.P.
        Pneumococcal vaccination rates in VHA patients with inflammatory bowel disease.
        Medicine (Baltimore). 2015; 94: e417
        • Kim H.
        • Melmed G.Y.
        Vaccinations in older adults with gastrointestinal diseases.
        Clin Geriatr Med. 2014; 30: 17-28
        • Dezfoli S.
        • Melmed G.
        Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression.
        Gastroenterol Hepatol (N Y). 2012; 8: 504-512
        • Urganci N.
        • Kalyoncu D.
        Response to hepatitis A and B vaccination in pediatric patients with celiac disease.
        J Pediatr Gastroenterol Nutr. 2013; 56: 408-411
      2. England DoPH. Immunisations against infectious diseases 2014. Available at: https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book. Accessed February 17, 2015.

      3. Public Health Agency of Canada. Canadian immunization guide. Part 3: vaccination of specific populations 2013. Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-07-eng.php. Accessed February 17, 2015.

      4. Robert Koch Institute-German Federal Ministry of Health. Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute 2014. Available at: http://www.rki.de/EN/Content/Prevention/Vaccination/recommandations/34_2014_engl_19215.pdf?__blob=publicationFile. Accessed February 17, 2015.

        • Danziger-Isakov L.
        • Kumar D.
        • the ASTIDCoP
        Vaccination in solid organ transplantation.
        Am J Transplant. 2013; 13: 311-317
        • Graff J.N.
        • Chamberlain E.D.
        Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.
        Core Evid. 2015; 10: 1-10
        • Ben-Nun A.
        • Wekerle H.
        • Cohen I.R.
        Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein.
        Nature. 1981; 292: 60-61
        • Vandenbark A.A.
        • Abulafia-Lapid R.
        Autologous T-cell vaccination for multiple sclerosis: a perspective on progress.
        BioDrugs. 2008; 22: 265-273
        • Hellings N.
        • Raus J.
        • Stinissen P.
        T-cell vaccination in multiple sclerosis: update on clinical application and mode of action.
        Autoimmun Rev. 2004; 3: 267-275
        • Karussis D.
        • Shor H.
        • Yachnin J.
        • et al.
        T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.
        PLoS One. 2012; 7: e50478
        • Trivedi S.
        • Zang Y.
        • Culpepper S.
        • et al.
        T cell vaccination therapy in an induced model of anti-RNP autoimmune glomerulonephritis.
        Clin Immunol. 2010; 137: 281-287
        • Gross C.C.
        • Wiendl H.
        Dendritic cell vaccination in autoimmune disease.
        Curr Opin Rheumatol. 2013; 25: 268-274
        • Maldonado R.A.
        • von Andrian U.H.
        How tolerogenic dendritic cells induce regulatory T cells.
        Adv Immunol. 2010; 108: 111-165
        • Yogev N.
        • Frommer F.
        • Lukas D.
        • et al.
        Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells.
        Immunity. 2012; 37: 264-275
        • Van Brussel I.
        • Lee W.P.
        • Rombouts M.
        • et al.
        Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?.
        Autoimmun Rev. 2014; 13: 138-150
        • Valaperti A.
        • Nishii M.
        • Germano D.
        • Liu P.P.
        • Eriksson U.
        Vaccination with Flt3L-induced CD8α+ dendritic cells prevents CD4+ T helper cell-mediated experimental autoimmune myocarditis.
        Vaccine. 2013; 31: 4802-4811
        • Wraith D.C.
        Therapeutic peptide vaccines for treatment of autoimmune diseases.
        Immunol Lett. 2009; 122: 134-136
        • Larche M.
        • Wraith D.C.
        Peptide-based therapeutic vaccines for allergic and autoimmune diseases.
        Nat Med. 2005; 11: S69-S76
        • Vandenbark A.A.
        • Morgan E.
        • Bartholomew R.
        • et al.
        TCR peptide therapy in human autoimmune diseases.
        Neurochem Res. 2001; 26: 713-730
        • Kang H.K.
        • Liu M.
        • Datta S.K.
        Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells.
        J Immunol. 2007; 178: 7849-7858
        • Zonneveld-Huijssoon E.
        • van Wijk F.
        • Roord S.
        • et al.
        TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis.
        Ann Rheum Dis. 2012; 71: 1706-1715
        • Gurr W.
        • Shaw M.
        • Herzog R.I.
        • Li Y.
        • Sherwin R.
        Vaccination with single chain antigen receptors for islet-derived peptides presented on I-A(g7) delays diabetes in NOD mice by inducing anergy in self-reactive T-cells.
        PLoS One. 2013; 8: e69464
        • Bielekova B.
        • Goodwin B.
        • Richert N.
        • et al.
        Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
        Nat Med. 2000; 6: 1167-1175
        • Kappos L.
        • Comi G.
        • Panitch H.
        • et al.
        Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.
        Nat Med. 2000; 6: 1176-1182
        • Barabas A.Z.
        • Cole C.D.
        • Lafreniere R.
        • Weir D.M.
        Regaining tolerance to a self-antigen by the modified vaccination technique.
        Clin Rev Allergy Immunol. 2013; 45: 193-201
        • Barabas A.Z.
        • Cole C.D.
        • Barabas A.D.
        • Barabas A.N.
        • Lafreniere R.
        Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique.
        Clin Dev Immunol. 2006; 13: 17-24
        • Barabas A.Z.
        • Cole C.D.
        • Barabas A.D.
        • Lafreniere R.
        Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease.
        Biologics. 2007; 1: 59-68
        • Nandakumar K.S.
        • Jansson A.
        • Xu B.
        • et al.
        A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis.
        PLoS One. 2010; 5: e13511
        • Kessel C.
        • Nandakumar K.S.
        • Peters F.B.
        • et al.
        A single functional group substitution in c5a breaks B cell and T cell tolerance and protects against experimental arthritis.
        Arthritis Rheum. 2014; 66: 610-621
        • Vergunst C.E.
        • Gerlag D.M.
        • Dinant H.
        • et al.
        Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.
        Rheumatology (Oxford). 2007; 46: 1773-1778
        • Mathian A.
        • Amoura Z.
        • Adam E.
        • et al.
        Active immunisation of human interferon alpha transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon alpha in sera from patients with systemic lupus erythematosus.
        Ann Rheum Dis. 2011; 70: 1138-1143
        • Lauwerys B.R.
        • Hachulla E.
        • Spertini F.
        • et al.
        Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
        Arthritis Rheum. 2013; 65: 447-456
        • Morimoto A.M.
        • Flesher D.T.
        • Yang J.
        • et al.
        Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.
        Arthritis Rheum. 2011; 63: 2407-2415
        • Shoenfeld Y.
        • Agmon-Levin N.
        ‘ASIA’—autoimmune/inflammatory syndrome induced by adjuvants.
        J Autoimmun. 2011; 36: 4-8
        • Hartwell B.L.
        • Antunez L.
        • Sullivan B.P.
        • et al.
        Multivalent nanomaterials: learning from vaccines and progressing to antigen-specific immunotherapies.
        J Pharm Sci. 2015; 104: 346-361
        • Kuroda Y.
        • Nacionales D.C.
        • Akaogi J.
        • Reeves W.H.
        • Satoh M.
        Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine.
        Biomed Pharmacother. 2004; 58: 325-337
        • Bagavant H.
        • Nandula S.R.
        • Kaplonek P.
        • Rybakowska P.D.
        • Deshmukh U.S.
        Alum, an aluminum-based adjuvant, induces Sjögren's syndrome-like disorder in mice.
        Clin Exp Rheumatol. 2014; 32: 251-255
        • Hawkes D.
        • Benhamu J.
        • Sidwell T.
        • Miles R.
        • Dunlop R.A.
        Revisiting adverse reactions to vaccines: a critical appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA).
        J Autoimmun. 2015; 59: 77-84